SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in June.
SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment of Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs.
- Positive data announced from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) - - Enrollment of 40 patients in Varseta-M Dose Optimization completed; data update expected in 2H 2026 to inform monotherapy dose
SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report first quarter financial results on Thursday, May 7, 2026, after the close of U.S.
SOUTH SAN FRANCISCO, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a leader in the field of masked, conditionally activated biologics, today announced the pricing of an underwritten public offering of 45,990,567 shares of its common stock at a price to the
SOUTH SAN FRANCISCO, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it has commenced an underwritten public offering of $250.0 million of shares of common stock and, in lieu
- Announced Positive Data from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY ® ADC in Patients with Advanced Colorectal Cancer (CRC) - - FDA interactions targeted for mid-year with goal to align on potential Varseta-M registrational trial design in late line CRC -
- Confirmed response rates in expansion cohorts of 32% at 10 mg/kg Q3W dose and 20% at 8.6 mg/kg Q3W - - Estimated progression free survival of 7.1 months at 10 mg/kg and 6.8 months at 8.6 mg/kg - - Grade 3 diarrhea rate of 10% in ongoing dose optimization cohorts - - FDA interactions targeted for
SOUTH SAN FRANCISCO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report full year 2025 financial results on Monday, March 16, 2026, before the open of U.S.